Tellgen Corp
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in… Read more
Tellgen Corp (300642) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.024x
Based on the latest financial reports, Tellgen Corp (300642) has a cash flow conversion efficiency ratio of 0.024x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥36.19 Million) by net assets (CN¥1.53 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tellgen Corp - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Tellgen Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tellgen Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tellgen Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ACAST AB (PUBL)
F:0PN
|
N/A |
|
Knight Therapeutics Inc
PINK:KHTRF
|
0.014x |
|
Zhejiang Baida Precision Mnfg
SHG:603331
|
0.085x |
|
Suzhou W Deane New Power Elec
SHG:603312
|
0.065x |
|
Bosung Power Technology Co. Ltd
KQ:006910
|
0.080x |
|
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
|
N/A |
|
BINEX Co. Ltd
KQ:053030
|
0.019x |
|
Rxsight Inc
NASDAQ:RXST
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Tellgen Corp (2012–2024)
The table below shows the annual cash flow conversion efficiency of Tellgen Corp from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.52 Billion | CN¥164.62 Million | 0.108x | +31.75% |
| 2023-12-31 | CN¥1.54 Billion | CN¥126.40 Million | 0.082x | -26.01% |
| 2022-12-31 | CN¥1.48 Billion | CN¥164.72 Million | 0.111x | +88.02% |
| 2021-12-31 | CN¥1.40 Billion | CN¥82.61 Million | 0.059x | -22.61% |
| 2020-12-31 | CN¥1.27 Billion | CN¥96.83 Million | 0.076x | -48.90% |
| 2019-12-31 | CN¥1.17 Billion | CN¥174.84 Million | 0.150x | -5.02% |
| 2018-12-31 | CN¥1.02 Billion | CN¥161.32 Million | 0.158x | +33.13% |
| 2017-12-31 | CN¥895.86 Million | CN¥106.00 Million | 0.118x | -65.30% |
| 2016-12-31 | CN¥288.65 Million | CN¥98.42 Million | 0.341x | +1.41% |
| 2015-12-31 | CN¥192.33 Million | CN¥64.67 Million | 0.336x | +7.97% |
| 2014-12-31 | CN¥131.05 Million | CN¥40.81 Million | 0.311x | +12.41% |
| 2013-12-31 | CN¥95.04 Million | CN¥26.33 Million | 0.277x | +193.02% |
| 2012-12-31 | CN¥72.47 Million | CN¥6.85 Million | 0.095x | -- |